IBDEI0DG ; ; 06-AUG-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 06, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18090,1,4,0)
 ;;=4^286.7
 ;;^UTILITY(U,$J,358.3,18090,1,5,0)
 ;;=5^Coagulation Defect(Any),Acquired
 ;;^UTILITY(U,$J,358.3,18090,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,18091,0)
 ;;=289.9^^116^1003^118
 ;;^UTILITY(U,$J,358.3,18091,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18091,1,4,0)
 ;;=4^289.9
 ;;^UTILITY(U,$J,358.3,18091,1,5,0)
 ;;=5^Thrombocytosis, Essential
 ;;^UTILITY(U,$J,358.3,18091,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,18092,0)
 ;;=451.9^^116^1003^119
 ;;^UTILITY(U,$J,358.3,18092,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18092,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,18092,1,5,0)
 ;;=5^Thrombophlebitis 
 ;;^UTILITY(U,$J,358.3,18092,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,18093,0)
 ;;=446.6^^116^1003^120
 ;;^UTILITY(U,$J,358.3,18093,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18093,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,18093,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(TTP)
 ;;^UTILITY(U,$J,358.3,18093,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,18094,0)
 ;;=286.4^^116^1003^123
 ;;^UTILITY(U,$J,358.3,18094,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18094,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,18094,1,5,0)
 ;;=5^Von Willebrand'S Disease
 ;;^UTILITY(U,$J,358.3,18094,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,18095,0)
 ;;=204.00^^116^1003^3
 ;;^UTILITY(U,$J,358.3,18095,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18095,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,18095,1,5,0)
 ;;=5^ALL, W/O Remission
 ;;^UTILITY(U,$J,358.3,18095,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,18096,0)
 ;;=204.01^^116^1003^2
 ;;^UTILITY(U,$J,358.3,18096,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18096,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,18096,1,5,0)
 ;;=5^ALL, In Remission
 ;;^UTILITY(U,$J,358.3,18096,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,18097,0)
 ;;=204.10^^116^1003^48
 ;;^UTILITY(U,$J,358.3,18097,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18097,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,18097,1,5,0)
 ;;=5^CLL, W/O Remission
 ;;^UTILITY(U,$J,358.3,18097,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,18098,0)
 ;;=204.11^^116^1003^46
 ;;^UTILITY(U,$J,358.3,18098,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18098,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,18098,1,5,0)
 ;;=5^CLL, In Remission
 ;;^UTILITY(U,$J,358.3,18098,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,18099,0)
 ;;=202.41^^116^1003^75
 ;;^UTILITY(U,$J,358.3,18099,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18099,1,4,0)
 ;;=4^202.41
 ;;^UTILITY(U,$J,358.3,18099,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspec Site
 ;;^UTILITY(U,$J,358.3,18099,2)
 ;;=^267472
 ;;^UTILITY(U,$J,358.3,18100,0)
 ;;=201.90^^116^1003^82
 ;;^UTILITY(U,$J,358.3,18100,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18100,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,18100,1,5,0)
 ;;=5^Hodgkin'S Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,18100,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,18101,0)
 ;;=785.6^^116^1003^88
 ;;^UTILITY(U,$J,358.3,18101,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18101,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,18101,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,18101,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,18102,0)
 ;;=200.20^^116^1003^89
 ;;^UTILITY(U,$J,358.3,18102,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18102,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,18102,1,5,0)
 ;;=5^Lymphoma, Burkitt'S, Unspecified Sites
 ;;^UTILITY(U,$J,358.3,18102,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,18103,0)
 ;;=202.00^^116^1003^91
 ;;^UTILITY(U,$J,358.3,18103,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18103,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,18103,1,5,0)
 ;;=5^Lymphoma, Low-Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,18103,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,18104,0)
 ;;=200.10^^116^1003^90
 ;;^UTILITY(U,$J,358.3,18104,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18104,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,18104,1,5,0)
 ;;=5^Lymphoma, Int Or High Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,18104,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,18105,0)
 ;;=273.3^^116^1003^92
 ;;^UTILITY(U,$J,358.3,18105,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18105,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,18105,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,18105,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,18106,0)
 ;;=203.00^^116^1003^105
 ;;^UTILITY(U,$J,358.3,18106,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18106,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,18106,1,5,0)
 ;;=5^Multiple Myeloma W/O Rem
 ;;^UTILITY(U,$J,358.3,18106,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,18107,0)
 ;;=203.01^^116^1003^104
 ;;^UTILITY(U,$J,358.3,18107,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18107,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,18107,1,5,0)
 ;;=5^Multiple Myeloma In Remission
 ;;^UTILITY(U,$J,358.3,18107,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,18108,0)
 ;;=238.6^^116^1003^107
 ;;^UTILITY(U,$J,358.3,18108,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18108,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,18108,1,5,0)
 ;;=5^Plasmacytoma Nos
 ;;^UTILITY(U,$J,358.3,18108,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,18109,0)
 ;;=205.00^^116^1003^6
 ;;^UTILITY(U,$J,358.3,18109,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18109,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,18109,1,5,0)
 ;;=5^AML, W/O Remission
 ;;^UTILITY(U,$J,358.3,18109,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,18110,0)
 ;;=205.01^^116^1003^5
 ;;^UTILITY(U,$J,358.3,18110,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18110,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,18110,1,5,0)
 ;;=5^AML, In Remission
 ;;^UTILITY(U,$J,358.3,18110,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,18111,0)
 ;;=205.10^^116^1003^51
 ;;^UTILITY(U,$J,358.3,18111,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18111,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,18111,1,5,0)
 ;;=5^CML, W/O Remission
 ;;^UTILITY(U,$J,358.3,18111,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,18112,0)
 ;;=205.11^^116^1003^50
 ;;^UTILITY(U,$J,358.3,18112,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18112,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,18112,1,5,0)
 ;;=5^CML, In Remission
 ;;^UTILITY(U,$J,358.3,18112,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,18113,0)
 ;;=289.0^^116^1003^54
 ;;^UTILITY(U,$J,358.3,18113,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18113,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,18113,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,18113,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,18114,0)
 ;;=238.4^^116^1003^108
 ;;^UTILITY(U,$J,358.3,18114,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18114,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,18114,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,18114,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,18115,0)
 ;;=V58.61^^116^1003^124
 ;;^UTILITY(U,$J,358.3,18115,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18115,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,18115,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,18115,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,18116,0)
 ;;=282.49^^116^1003^116
 ;;^UTILITY(U,$J,358.3,18116,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18116,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,18116,1,5,0)
 ;;=5^Thalassemia Nec
 ;;^UTILITY(U,$J,358.3,18116,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,18117,0)
 ;;=289.89^^116^1003^15
 ;;^UTILITY(U,$J,358.3,18117,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18117,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,18117,1,5,0)
 ;;=5^Blood Diseases Nec
 ;;^UTILITY(U,$J,358.3,18117,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,18118,0)
 ;;=238.79^^116^1003^87
 ;;^UTILITY(U,$J,358.3,18118,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18118,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,18118,1,5,0)
 ;;=5^Lymph/Hematpoitc Tis Nec
 ;;^UTILITY(U,$J,358.3,18118,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,18119,0)
 ;;=287.30^^116^1003^109
 ;;^UTILITY(U,$J,358.3,18119,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18119,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,18119,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,18119,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,18120,0)
 ;;=288.09^^116^1003^7
 ;;^UTILITY(U,$J,358.3,18120,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18120,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,18120,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,18120,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,18121,0)
 ;;=284.81^^116^1003^14
 ;;^UTILITY(U,$J,358.3,18121,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18121,1,4,0)
 ;;=4^284.81
 ;;^UTILITY(U,$J,358.3,18121,1,5,0)
 ;;=5^Aplastic Due To Drugs
 ;;^UTILITY(U,$J,358.3,18121,2)
 ;;=^335245
 ;;^UTILITY(U,$J,358.3,18122,0)
 ;;=284.89^^116^1003^13
 ;;^UTILITY(U,$J,358.3,18122,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18122,1,4,0)
 ;;=4^284.89
 ;;^UTILITY(U,$J,358.3,18122,1,5,0)
 ;;=5^Aplastic Anemia due to Chr disease
 ;;^UTILITY(U,$J,358.3,18122,2)
 ;;=^87880
 ;;^UTILITY(U,$J,358.3,18123,0)
 ;;=284.9^^116^1003^11
 ;;^UTILITY(U,$J,358.3,18123,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18123,1,4,0)
 ;;=4^284.9
 ;;^UTILITY(U,$J,358.3,18123,1,5,0)
 ;;=5^Aplastic Anemia NOS
 ;;^UTILITY(U,$J,358.3,18123,2)
 ;;=^7020
 ;;^UTILITY(U,$J,358.3,18124,0)
 ;;=289.84^^116^1003^117
 ;;^UTILITY(U,$J,358.3,18124,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18124,1,4,0)
 ;;=4^289.84
 ;;^UTILITY(U,$J,358.3,18124,1,5,0)
 ;;=5^Thrombocytopenia,Heparin Induced
 ;;^UTILITY(U,$J,358.3,18124,2)
 ;;=^336542
 ;;^UTILITY(U,$J,358.3,18125,0)
 ;;=204.02^^116^1003^1
 ;;^UTILITY(U,$J,358.3,18125,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18125,1,4,0)
 ;;=4^204.02
 ;;^UTILITY(U,$J,358.3,18125,1,5,0)
 ;;=5^ALL, In Relapse
 ;;^UTILITY(U,$J,358.3,18125,2)
 ;;=^336465
 ;;^UTILITY(U,$J,358.3,18126,0)
 ;;=204.12^^116^1003^47
 ;;^UTILITY(U,$J,358.3,18126,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18126,1,4,0)
 ;;=4^204.12
 ;;^UTILITY(U,$J,358.3,18126,1,5,0)
 ;;=5^CLL, In Remission
 ;;^UTILITY(U,$J,358.3,18126,2)
 ;;=^336466
 ;;^UTILITY(U,$J,358.3,18127,0)
 ;;=204.21^^116^1003^114
